Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02424123
Other study ID # LOCAL/2014/ET-02
Secondary ID 2015-A00157-42
Status Completed
Phase
First received
Last updated
Start date October 11, 2016
Est. completion date July 30, 2020

Study information

Verified date December 2023
Source Centre Hospitalier Universitaire de Nimes
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Seizures represent an important clinical problem, accounting for at least 40% of adult onset epilepsy. Predicting seizure recurrence in subjects experiencing a first seizure is difficult due to the lack of prognostic biomarkers. Recent evidence has indicated that blood-brain barrier (BBB) dysfunction constitutes an etiological factor to seizures. In particular, it has been shown that modification of BBB permeability is associated with seizure activity. In addition, it was demonstrated that BBB permeability can be assessed by measuring serum level of the protein S100B. Based on these data and considerations the investigators will test whether the extent of BBB damage at time of first seizure is predictive for seizure recurrence. The main objective of this study is to evaluate the association between the absolute (ng/ml) serum S100B levels (measured at time of the first seizure) and the experience, or not, of seizure recurrence within one year of follow-up.


Description:

The secondary objectives of this study are to investigate the: A) Prognostic capacity of serum S100B levels to predict seizure recurrence. B) Association between the variation (%) of serum S100B levels between first seizure episode and scheduled follow-up (D14-D28) and seizure recurrence. C) Correlation of S100B with IL-1b, IL-6, NSE serum levels at the same time points. D) Association of serology data with: a) EEG profile (normal/abnormal); b) recurrence of seizures (Y/N). E) Comparison of S100B serum levels in lesional vs non-lesional patients. F) Establishment of a bio-bank (serum and cells).


Recruitment information / eligibility

Status Completed
Enrollment 37
Est. completion date July 30, 2020
Est. primary completion date July 30, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 59 Years
Eligibility Inclusion Criteria: - The patient has been correctly informed. - The patient must have given his informed and signed consent. - The patient must be insured or beneficiary of a health insurance plan. - The patient is at least (=) 18 years old and less than (<) 60 years old. - The patient has experienced a first generalized, epileptic seizure (patients with partial onset and secondary generalization can also be included). - The seizure has occurred less than 24 hours ago. Exclusion Criteria: - The patient is participating in another study that may interfere with the results or conclusions of this study. - Within the past three months, the patient has participated in another study that may interfere with the results or conclusions of this study. - The patient is in an exclusion period determined by a previous study. - The patient is under judicial protection. - The patient refuses to sign the consent. - It is impossible to correctly inform the patient. - The patient is pregnant or breast-feeding (MRI contraindicated). - Patient has a previous abnormal brain imaging (MRI). - Patient has abnormal biological tests for toxicology (alcohol, cocaine and cannabis tests), blood ionogram (hyponatremia <130mM), liver enzymes (>5N), inflammatory syndrome (elevated C-reactive protein).

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France APHM - Hôpital Nord Marseille Cedex 20
France CHRU de Nîmes - Hôpital Universitaire Carémeau Nîmes Cedex 09

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Nimes

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Serum S100B level ng/ml Day 0 (T0+6 hours)
Primary Serum S100B level ng/ml Day 0 (T0+12 hours)
Primary Seizure recurrence within 1 year yes/no 12 months
Secondary Serum S100B level ng/ml Between days 14 and 28
Secondary Serum S100B level ng/ml 6 months
Secondary Serum S100B level ng/ml 12 months
Secondary Serum S100B level ng/ml at time of 2nd seizure (expected max of 12 months)
Secondary Serum IL-1b level pg/mL Day 0 (T0+6 hours)
Secondary Serum IL-1b level pg/mL Day 0 (T0+12 hours)
Secondary Serum IL-1b level pg/mL Between days 14 and 28
Secondary Serum IL-6 level pg/mL Day 0 (T0+6 hours)
Secondary Serum IL-6 level pg/mL Day 0 (T0+12 hours)
Secondary Serum IL-6 level pg/mL Between days 14 and 28
Secondary Serum NSE level µg/dL Day 0 (T0+6 hours)
Secondary Serum NSE level µg/dL Day 0 (T0+12 hours)
Secondary Serum NSE level µg/dL Between days 14 and 28
Secondary Electro encephalogram profile Day 0
Secondary Electro encephalogram profile Between days 14 and 28
See also
  Status Clinical Trial Phase
Completed NCT04595513 - Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants Phase 1/Phase 2
Completed NCT02909387 - Adapting Project UPLIFT for Blacks in Georgia N/A
Completed NCT05552924 - Self Acupressure on Fatigue and Sleep Quality in Epilepsy Patients N/A
Terminated NCT01668654 - Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS Phase 3
Not yet recruiting NCT05068323 - Impact of Interictal Epileptiform Activity on Some Cognitive Domains in Newly Diagnosed Epileptic Patients N/A
Completed NCT03994718 - Creative Arts II Study N/A
Recruiting NCT04076449 - Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
Completed NCT00782249 - Trial Comparing Different Stimulation Paradigms in Patients Treated With Vagus Nerve Stimulation for Refractory Epilepsy N/A
Completed NCT03683381 - App-based Intervention for Treating Insomnia Among Patients With Epilepsy N/A
Recruiting NCT05101161 - Neurofeedback Using Implanted Deep Brain Stimulation Electrodes N/A
Active, not recruiting NCT06034353 - Impact of Pharmacist-led Cognitive Behavioral Intervention on Adherence and Quality of Life of Epileptic Patients N/A
Recruiting NCT05769933 - Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
Not yet recruiting NCT06408428 - Glioma Intraoperative MicroElectroCorticoGraphy N/A
Not yet recruiting NCT05559060 - Comorbidities of Epilepsy(Cognitive and Psychiatric Dysfunction)
Completed NCT02952456 - Phenomenological Approach of Epilepsy in Patients With Epilepsy
Completed NCT02646631 - Behavioral and Educational Tools to Improve Epilepsy Care N/A
Completed NCT02977208 - Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use Phase 4
Recruiting NCT02539134 - TAK-935 Multiple Rising Dose Study in Healthy Participants Phase 1
Completed NCT02491073 - Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL) N/A
Terminated NCT02757547 - Transcranial Magnetic Stimulation for Epilepsy N/A